Clinical Utility of Cxbladder to Headline at AUA 2024

CLINICAL UTILITY OF CXBLADDER TO HEADLINE AT AUA 2024

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) released a routine marketing communication this morning to investors, customers, and the media on its activities at the American Urological Association (AUA) Annual Meeting on May 3 - 6 to promote the results of its STRATA study. These activities had been previously described in our Q4 24 Investor Update released on 9 April, 2024.

Pacific Edge incorrectly stated in a footnote of this morning’s marketing communication that the information contained in it was ‘material’, and is issuing this communication to the NZX and ASX as a correction. Pacific Edge has already corrected the statement in a revised marketing email. Pacific Edge maintains the view that the information is not material as defined by the NZX listing rules since the results of the study and the AUA’s interest in it were disclosed in the company’s Q4 24 Investor Update.

Notably, in the Q4 24 Investor Update the company disclosed that the abstract of the study had been accepted as a podium presentation at the AUA and that a manuscript on the study requested by the AUA for publication in the issue of the Journal of Urology that will coincide with the AUA Annual Meeting was in the final stages of peer-review. The peer-review process has since been completed and the manuscript is confirmed to be published.

For more information:

Investors:
Dr Peter Meintjes
Chief Executive
Pacific Edge
P: +64 22 032 1263

Media:
Richard Inder
The Project
P: +64 21 645 643


OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com
Cxbladder is a urine-based genomic biomarker test optimized for the detection and surveillance of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy.

Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder has been trusted by over 4,400 US urologists in the diagnosis and management of more than 100,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 75% of the population via public healthcare and all residents have the option of buying the test online.

---

Announcement PDF